Profound Medical Corp. (TSE:PRN - Get Free Report) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as C$8.66 and last traded at C$9.34, with a volume of 1674 shares traded. The stock had previously closed at C$9.28.
Analyst Upgrades and Downgrades
Separately, Raymond James upgraded Profound Medical to a "strong-buy" rating in a report on Saturday, November 9th.
Read Our Latest Research Report on PRN
Profound Medical Price Performance
The company has a debt-to-equity ratio of 16.95, a current ratio of 8.61 and a quick ratio of 14.98. The company's 50 day moving average is C$10.40 and its 200 day moving average is C$11.22. The stock has a market cap of C$209.30 million, a price-to-earnings ratio of -5.15 and a beta of 0.81.
Profound Medical (TSE:PRN - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported C($0.52) earnings per share for the quarter, missing analysts' consensus estimates of C($0.42) by C($0.10). During the same period last year, the firm earned ($0.35) EPS. Research analysts forecast that Profound Medical Corp. will post -1.9000001 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director Arun Menawat Dr. bought 20,000 shares of the firm's stock in a transaction on Tuesday, December 10th. The stock was bought at an average cost of C$10.65 per share, for a total transaction of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino bought 13,333 shares of the company's stock in a transaction on Tuesday, December 10th. The stock was bought at an average cost of C$10.65 per share, for a total transaction of C$141,996.45. 8.62% of the stock is currently owned by company insiders.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Featured Stories
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
